Cingulate Inc. (CING)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cingulate Inc. (CING) trades at $5.30 with AI Score 28/100 (Grade F). Cingulate Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for attention-deficit/hyperactivity disorder (ADHD). Market cap: $29.71M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for CING: CING does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CING against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CING: 1/1 perspectives are bearish.
How is this calculated? →Cingulate Inc. (CING) Healthcare & Pipeline Overview
Cingulate Inc. is a clinical-stage biopharmaceutical company focusing on ADHD treatments, with lead candidates CTx-1301 (dexmethylphenidate) in Phase 3 trials and CTx-1302 (dextroamphetamine) under development. The company aims to provide improved dosing and symptom control for patients with attention-deficit/hyperactivity disorder.
What Is the Investment Thesis for CING?
Cingulate Inc. presents a focused investment opportunity within the ADHD treatment market. The company's lead candidate, CTx-1301, is in Phase 3 clinical trials, representing a near-term catalyst for potential value creation. Positive trial results and subsequent regulatory approval could drive significant revenue growth. The company's second candidate, CTx-1302, offers further pipeline expansion and potential for market diversification. However, the company's small market capitalization of $29.71M and limited resources pose risks. Dependence on successful clinical trial outcomes and regulatory approvals are critical factors. Investor sentiment and market conditions could significantly impact the stock's performance.
Based on FMP financials and quantitative analysis
CING Key Highlights
- CTx-1301, a dexmethylphenidate formulation, is currently in Phase 3 clinical trials for ADHD treatment.
- CTx-1302, a dextroamphetamine formulation, is under development for ADHD, potentially offering a differentiated treatment option.
- The company is also developing CTx-2103 for anxiety disorders, expanding its therapeutic focus.
- Cingulate Inc. operates with a lean team of 13 employees, reflecting a focus on operational efficiency.
- The company's market capitalization is $0.03 billion, indicating its small-cap status.
Who Are CING's Competitors?
CING is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LLY Eli Lilly and Company | $1202.56 | -0.94% | $1.13T | 98 |
| SHPG Shire plc | $179.20 | +0.00% | 60 | |
| ABBV AbbVie Inc. | $255.67 | -2.07% | $451.72B | 78 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CING's Key Strengths?
- Focus on developing innovative treatments for ADHD.
- Lead product candidate (CTx-1301) in Phase 3 clinical trials.
- Potential for improved dosing and symptom control compared to existing treatments.
- Experienced management team with expertise in drug development.
What Are CING's Weaknesses?
- Limited financial resources and small market capitalization.
- Dependence on successful clinical trial outcomes and regulatory approvals.
- Competition from established pharmaceutical companies with larger market share.
- Limited commercialization experience.
What Could Drive CING Stock Higher?
- Data readout from CTx-1301 Phase 3 clinical trials, expected within the next 12-18 months.
- Potential FDA submission for CTx-1301 following successful Phase 3 results.
- Continued development and advancement of CTx-1302 through preclinical and clinical studies.
- Potential strategic partnerships or collaborations to accelerate drug development.
What Are the Key Risks for CING?
- Financial-distress signal — its Altman Z-Score of -6.84 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive results in CTx-1301 Phase 3 clinical trials.
- Regulatory setbacks or delays in FDA approval process.
- Competition from established pharmaceutical companies and generic ADHD medications.
- Dependence on securing additional funding to support ongoing clinical trials and operations.
What Are the Growth Opportunities for CING?
- Successful Completion of CTx-1301 Phase 3 Trials: The successful completion of Phase 3 clinical trials for CTx-1301 represents a significant growth opportunity for Cingulate. Positive results would pave the way for regulatory approval and commercialization, potentially capturing a share of the ADHD treatment market, estimated to reach billions of dollars annually. The timeline for completion and data release is anticipated within the next 12-18 months, making it a near-term catalyst.
- Advancement of CTx-1302 Development: The continued development of CTx-1302, a dextroamphetamine formulation, offers another growth avenue. If successful, CTx-1302 could provide a differentiated treatment option for ADHD patients, expanding Cingulate's product portfolio and market reach. The development timeline is estimated at 2-3 years, with potential for clinical trials and regulatory submissions.
- Expansion into Anxiety Disorder Treatment with CTx-2103: Cingulate's development of CTx-2103 for anxiety disorders represents a strategic diversification opportunity. The anxiety disorder market is substantial, and a successful treatment could significantly expand Cingulate's revenue streams. Clinical trials and regulatory approvals are required, with a timeline of 3-5 years for potential commercialization.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could accelerate Cingulate's drug development programs and provide access to additional funding and expertise. Such collaborations could enhance the company's credibility and increase the likelihood of successful product launches. The timeline for securing partnerships is ongoing and dependent on market conditions and company performance.
- Geographic Expansion: While currently focused on the US market, Cingulate could explore opportunities for geographic expansion into international markets, such as Europe and Asia. This would require regulatory approvals in each region but could significantly increase the company's potential customer base and revenue. The timeline for international expansion is estimated at 5+ years, contingent on successful US commercialization.
What Opportunities Does CING Have?
- Successful commercialization of CTx-1301 and CTx-1302.
- Expansion into new therapeutic areas, such as anxiety disorders.
- Strategic partnerships with larger pharmaceutical companies.
- Increasing prevalence of ADHD and demand for improved treatments.
What Threats Does CING Face?
- Failure to achieve positive clinical trial results.
- Regulatory setbacks and delays in drug approval.
- Competition from generic ADHD medications.
- Changes in healthcare regulations and reimbursement policies.
What Are CING's Competitive Advantages?
- Proprietary drug formulations with potential for improved efficacy and safety.
- Patent protection for their drug candidates, providing market exclusivity.
- Clinical trial data demonstrating the benefits of their treatments.
- First-mover advantage in developing specific ADHD treatment options.
What Does CING Do?
Founded in 2012 and headquartered in Kansas City, Kansas, Cingulate Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative treatments for attention-deficit/hyperactivity disorder (ADHD). The company's mission is to address the unmet needs of patients with ADHD by developing product candidates that offer improved dosing regimens and symptom control. Cingulate's lead product candidates include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to provide a rapid onset and extended duration of effect. CTx-1301 is currently in Phase 3 clinical trials. Additionally, Cingulate is developing CTx-2103 for the treatment of anxiety disorders, expanding its focus beyond ADHD. The company's pipeline reflects its commitment to addressing a range of mental health conditions with significant unmet medical needs. Cingulate operates with a lean team of 13 employees, emphasizing efficiency and strategic partnerships to advance its clinical programs.
What Products and Services Does CING Offer?
- Develop product candidates for the treatment of attention-deficit/hyperactivity disorder (ADHD).
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Focus on developing improved dosing regimens and symptom control for ADHD patients.
- Advance CTx-1301 (dexmethylphenidate) through Phase 3 clinical trials.
- Develop CTx-1302 (dextroamphetamine) as another potential ADHD treatment option.
- Explore treatments for anxiety disorders with CTx-2103.
How Does CING Make Money?
- Develop and patent novel drug formulations for ADHD and anxiety disorders.
- Conduct clinical trials to demonstrate the safety and efficacy of their drug candidates.
- Seek regulatory approval from the FDA for commercialization.
- Potentially partner with larger pharmaceutical companies for manufacturing and distribution.
What Industry Does CING Operate In?
The biotechnology industry is characterized by high risk and high reward, with companies like Cingulate Inc. focused on developing novel therapies for specific medical conditions. The ADHD treatment market is a significant segment within the broader pharmaceutical landscape, driven by increasing diagnosis rates and demand for improved treatment options. Competition includes established pharmaceutical companies and other emerging biotech firms developing innovative ADHD therapies. Cingulate's success depends on its ability to navigate the regulatory landscape, secure funding, and demonstrate clinical efficacy and safety of its product candidates.
Who Are CING's Key Customers?
- Patients diagnosed with attention-deficit/hyperactivity disorder (ADHD).
- Healthcare providers who prescribe ADHD medications.
- Pharmacies that dispense ADHD medications.
- Potentially, patients with anxiety disorders if CTx-2103 is approved.
Key Financial Metrics
Return on assets is -89.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -72.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -104.4%, the inverse of the P/E and a quick read on earnings relative to price.
Cingulate Inc. (CING) Valuation Context
Valued at $29.71M, CING is classified as a micro-cap stock. Relative to its peer group, CING's quantitative score of 28/100 is below the peer average of 79/100.
Company Profile
Cingulate Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Kansas City, US. The company is led by CEO Shane J. Schaffer. CING has traded publicly since 2021.
F-Score 3/9Financial Health
Cingulate Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.84 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Cingulate Inc. revenue of about $2.9M for fiscal 2026, with EPS near $-2.42. The estimate reflects 4 contributing analysts.
CING Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in the long-term value of their shares.
- Community sentiment has shown increasing optimism, with discussions highlighting potential breakthroughs in Cingulate's product pipeline.
- Positive developments in clinical trials have garnered attention, reinforcing the belief that the company is on the verge of significant advancements in its field.
- Increased media coverage has led to heightened awareness of Cingulate's innovative approaches, attracting new investors and interest from the trading community.
Bear Case
- Concerns over cash flow sustainability have been raised, as some investors question the company's ability to fund ongoing operations without dilution.
- Negative sentiment from a portion of the community stems from skepticism about the scalability of Cingulate's products in a competitive market.
- Recent regulatory challenges have created uncertainty, leading some traders to adopt a more cautious stance on the company's future performance.
- Market perception remains mixed, with some analysts expressing doubts about the long-term viability of Cingulate's business model amid industry competition.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
CING Latest News
-
Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday
benzinga · Jun 9, 2026
-
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
benzinga · Jun 8, 2026
-
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga · Jun 3, 2026
CING Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CING.
Price Targets
Wall Street price target analysis for CING.
CING MoonshotScore
What does this score mean?
The MoonshotScore rates CING's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Shane J. Schaffer
CEO
Shane J. Schaffer serves as the CEO of Cingulate Inc., bringing extensive experience in the pharmaceutical and biotechnology industries. His background includes leadership roles in various companies, where he focused on strategic planning, business development, and commercialization of pharmaceutical products. Schaffer's expertise spans across multiple therapeutic areas, including central nervous system disorders. His experience in navigating the regulatory landscape and securing funding for drug development programs is crucial for Cingulate's success.
Track Record: Under Shane Schaffer's leadership, Cingulate Inc. has advanced its lead product candidate, CTx-1301, into Phase 3 clinical trials. He has overseen the company's strategic direction, focusing on developing innovative treatments for ADHD. His ability to attract investment and build a strong team has been instrumental in driving Cingulate's progress. Schaffer has also emphasized operational efficiency and strategic partnerships to maximize the company's resources.
Cingulate Inc. Healthcare Stock: Key Questions Answered
What does Cingulate Inc. do?
Cingulate Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for attention-deficit/hyperactivity disorder (ADHD) and anxiety disorders. Their lead product candidates, CTx-1301 and CTx-1302, are designed to provide improved dosing regimens and symptom control for ADHD patients. CTx-1301 is currently in Phase 3 clinical trials, representing a near-term opportunity for potential regulatory approval and commercialization. The company also focuses on developing CTx-2103 for anxiety disorders, expanding its therapeutic focus beyond ADHD. Cingulate operates with a lean team and emphasizes strategic partnerships to advance its clinical programs.
What do analysts say about CING stock?
As a clinical-stage biopharmaceutical company, Cingulate Inc. is subject to analyst evaluations based on the potential of its drug candidates and the progress of its clinical trials. Analyst ratings and price targets may vary depending on their assessment of the company's pipeline, regulatory prospects, and market opportunities. Key valuation metrics include the potential peak sales of CTx-1301 and CTx-1302, as well as the probability of success for each drug candidate. Growth considerations include the increasing prevalence of ADHD and the demand for improved treatment options. However, analyst opinions should be viewed as one factor among many in making investment decisions.
What are the main risks for CING?
Cingulate Inc. faces several key risks inherent to the biotechnology industry. A primary risk is the potential failure to achieve positive results in its clinical trials, particularly for CTx-1301, which is currently in Phase 3. Regulatory setbacks or delays in the FDA approval process could also significantly impact the company's prospects. Competition from established pharmaceutical companies and generic ADHD medications poses an ongoing challenge. Additionally, Cingulate is dependent on securing additional funding to support its ongoing clinical trials and operations, which could dilute existing shareholders or limit the company's growth potential.
What are the key factors to evaluate for CING?
Cingulate Inc. (CING) holds an AI score of 28/100 (low). Not financial advice.
How frequently does CING data refresh on this page?
CING prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CING's recent stock price performance?
Cingulate Inc. (CING) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on developing innovative treatments for ADHD. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CING overvalued or undervalued right now?
Valuing Cingulate Inc. (CING) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CING?
Before investing in Cingulate Inc. (CING), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.
- Investment in biotechnology companies involves significant risk.